Cargando…
The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation
Patients who have undergone hematopoietic stem cell transplantation (HSCT) for hematological disease experience high mortality when infected by coronavirus disease 2019 (COVID-19). However, the safety and efficacy of the COVID-19 vaccine in HSCT patients remain to be investigated. We prospectively e...
Autores principales: | Watanabe, Marika, Yakushijin, Kimikazu, Funakoshi, Yohei, Ohji, Goh, Hojo, Wataru, Sakai, Hironori, Saeki, Miki, Hirakawa, Yuri, Matsumoto, Sakuya, Sakai, Rina, Nagao, Shigeki, Kitao, Akihito, Miyata, Yoshiharu, Koyama, Taiji, Saito, Yasuyuki, Kawamoto, Shinichiro, Ito, Mitsuhiro, Murayama, Tohru, Matsuoka, Hiroshi, Minami, Hironobu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874528/ https://www.ncbi.nlm.nih.gov/pubmed/35214617 http://dx.doi.org/10.3390/vaccines10020158 |
Ejemplares similares
-
A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients
por: Watanabe, Marika, et al.
Publicado: (2022) -
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer
por: Funakoshi, Yohei, et al.
Publicado: (2022) -
Increase in Antibody Titers Following Sars-Cov-2 Vaccination Remains Limited for More Than 3 Years after Final Dose of Anti-CD20 Antibody
por: Funakoshi, Yohei, et al.
Publicado: (2021) -
Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody
por: Funakoshi, Yohei, et al.
Publicado: (2022) -
Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination
por: Funakoshi, Yohei, et al.
Publicado: (2022)